In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
207 News Items found
Bridget Anderson
Fecal Transplants Boost Helpful Microbiota for Stem Cell Transplant Patients

To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.
Three syringes stuck into an orange and white bull’s-eye
In the Clinic
Drug Targeting Genetic Mutation Works across All Tumor Types

A drug effective in all cancer types with a mutation called a TRK fusion could be the first ever developed simultaneously in adults and children.
Selwyn M. Vickers, MD, FACS
A Message From MSK’s President and CEO, Dr. Selwyn Vickers

In cancer care, firsts make a difference. At MSK, we are constantly improving how we help people with those important firsts. Dr. Selwyn Vickers writes about the latest developments at MSK and the encouraging evidence that we are making progress in our mission of ending cancer for life.
Illustration of human neck and head with thyroid gland highlighted and tumor growing on gland.
Science Byte
Breaking Bad: Researchers Find Mutations that Turn Thyroid Cancers Deadly

MSK researchers identify mutations that convert nonthreatening thyroid tumors into aggressive cancers.
Detail shot of a nurse holding hands with a patient
MSK Research Highlights, May 10, 2024

New MSK research measures unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies; investigates oral bacteria’s link to gut microbiota depletion with implications for cancer patients; and shows how a universal opt-out approach could help more cancer patients quit smoking.
An MSK researcher at work in the lab
MSK Research Highlights August 31, 2026

New MSK research identifies a tumor-secreted protein that primes the lungs for metastasis; shows how a new drug combination improves survival in patients with advanced clear cell renal cell carcinoma; and find a three-drug combination works in most patients newly diagnosed with follicular lymphoma.
MSK researcher in a lab
MSK Research Highlights, August 24, 2023

New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.
Close up of an MSK researcher's hands and arms handling test tubes in the lab.
Gerstner Sloan Kettering Graduate Students Receive 2024-2025 Fellowships

Nine GSK PhD students were awarded competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Dr. Joan Massagué, Sloan Kettering Institute Director received the Pezcoller Foundation-AACR International Award for Cancer Research and was named an AACR fellow at AACR16.
Announcement
News from #AACR16: Targeted Therapy Breakthrough, Improved Survival in Melanoma, and Benefits of Gut Bugs

Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.
Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in JAMA Oncology.